Specifications Molecular Formula CHNO Molecular Weight 5302.3 g/mol Receptor Targets GLP-1R + GIPR + GCGR (triple agonist) Form Lyophilized white powder Storage (unopened) -20C, protected from light Storage (reconstituted) 2-8C, use within 30 days Reconstitution & storage Add 2 mL of bacteriostatic water to the 10 mg vial for a 5 mg/mL working concentration
Reconstituted solutions should be refrigerated at 4C and used within 4-6 weeks
Retatrutide is still being studied and is not yet approved for general use, which simply means we rely on current data to guide expectations instead of making promises
The GLP-1 pathway plays a pivotal role in regulating blood sugar levels and promoting overall health
Reduced Cardiovascular Risk: By promoting weight loss and improving metabolic profiles (blood glucose, cholesterol), Retatrutide can reduce the risk of cardiovascular diseases, which are often linked to obesity and diabetes
There is also ongoing research into peptide activity in areas such as growth hormone release, metabolic regulation, and skin appearance
%20(1).png)
